









Primate adult brain cell autotransplantation, a new tool for brain repair?
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Abstract
If successful, autologous brain cell transplantation is an attractive approach to repair lesions and restore function of the central nervous
system. We demonstrate that monkey adult brain cells obtained from cortical biopsy and kept in culture for 4 weeks exhibit neural progenitor
characteristics. After reimplantation into a lesion area of the donor cerebral cortex, these cells can successfully survive and acquire neuronal
characteristics over time. These results open new perspectives in the field of brain repair and may lead to future clinical applications.
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Introduction
Using neural grafts to restore function after lesions of the
central nervous system is a challenging strategy. Most of the
transplantation experience acquired the last two decades was
focused on fetal neuronal grafts (Isacson, 2003; Lindvall et
al., 2004; Richardson et al., 2004). The objective was to
replace degenerated neurons in pathologies, such as
Parkinson’s and Huntington’s disease, characterized by
degeneration restricted to a limited brain area (Bjorklund
and Lindvall, 2000; Brazel and Rao, 2004; Freed et al.,
2001; Palfi et al., 1998; Park et al., 2002; Redmond, 2002;
Redmond et al., 2001). However, despite the great
enthusiasm generated by this approach, ethical controver-
sies, immune rejection, and lack of fetal donors remain a
major problem. Therefore, autotransplantation of adult brain
cells represents an attractive restoration alternative to bypass
the caveats of fetal grafting. Efforts have been made over the
past few years to develop appropriate methods to prepare
long-term primocultures from primate cortical biopsies
(Johansson et al., 1999; Kempermann and Gage, 1999;
McKay, 1997; Palm et al., 2000; Uchida et al., 2000). After
optimization of the procedure for brain cell culture
preparation, using medium with preselected fetal calf serum
(pFCS), we succeeded in producing long-term primocul-
tures of adult human brain cells from temporal lobe tissues
obtained from epilepsy and trauma neurosurgical patients
(Brunet et al., 2002). In a previous study, we have also
described the possibility of cryopreserving adult brain tissue
to obtain brain cells with characteristics the similar to
primoculture (Brunet et al., 2003). Furthermore previous
studies suggest that the reconstruction and repair of cortical
circuitry responsible for sensory, motor, or cognitive
function may be possible by allogeneic stem cell trans-
plantation in the mature mouse neocortex (Hernit-Grant and
Macklis, 1996). Here, we propose to demonstrate the
feasibility of autotransplantation from brain biopsy to re-
implantation of cultured brain cells in a non-human primate
model of motor cortex lesion (Fig. 1).
Results and discussion
As for human brain cell culture, using medium with
preselected fetal calf serum (pFCS), we succeeded in
producing long-term primocultures of brain cells from
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cortical biopsies of non-human primates (Macaca fascicu-
laris) with similar results. In vitro, we could demonstrate
that both human and monkey adult brain cells express
neuroectodermal and progenitor markers such as GFAP,
neurofilament, vimentin, or nestin (data not shown) as we
described in a previous studies (Brunet et al., 2002).
In the present study we hypothesized that the monkey
cortical grey matter cells kept in vitro for 1 month could
survive in vivo, when reimplanted in a normal and a
lesioned cortical area of the donor. To obtain the brain cells,
a right prefrontal open cortical biopsy was performed in
three adult monkeys (6–9 years old; 4–7 kg). The cells
from grey matter enriched fraction were then processed in
vitro as described for human brain cells previously (Brunet
et al., 2002). However, in order to facilitate reimplantation,
they were cultured in suspension under slow agitation (50–
75 rpm with an ES-W shaker-Kuhner). Cells obtained
presented the same morphological characteristics and
expressed the same markers (GFAP, vimentin, and nestin),
as observed in monolayer cultures. Two weeks after cortical
biopsy, as previously described in detail (Liu and Rouiller,
1999), an ibotenic acid excitotoxic lesion was performed in
an area of the left primary motor cortex (M1) of the
monkeys, restricted to the hand representation. Three weeks
later, the cells were stereotaxically re-implanted into the
lesioned M1, and into an intact parietal cortical site. Just
prior to reimplantation, cells were stained for tracking with
fluorescent viable dyes that irreversibly bind to cell
membranes (Fig. 1D) (PKH26 for implanted cells in the
ibotenic-lesioned site and PKH67 for implanted cells in the
intact site) as already described for intracerebrally trans-
planted cells (Haas et al., 2000).
One month after re-implantation, the first monkey was
sacrificed, the brain was removed and 8 series of 50-Am-
thick sections were prepared with a cryotome. Sections
were observed after Nissl staining or directly under
fluorescence microscope after mounting in Vectashield
containing DAPI to counterstain nuclei in blue to detect
PKH26- or PKH67-stained cells. Analysis confirmed that
the autotransplanted cortical grey matter cells could survive
equally, at least 1 month, in both the lesioned and the
intact sites (Figs. 2A and B). Moreover, migration was
observed in distal areas and in the direction of the
subventricular zone. Immunohistochemistry revealed that
the large majority of the implanted cells were nestin
positive (Figs. 2C–E).
Three months after reimplantation, two other monkeys
were sacrificed, and brains were processed as above.
Surprisingly, no PKH67-labeled cells were detected in the
non-lesion reimplantation site and nowhere else in the
whole brain (data not shown). This observation confirms
that PKH could not be picked up by resident cells.
However, PKH26-labeled cells were observed up to 1 cm
away from the injection site, surrounding the ibotenic acid
lesion (Figs. 3A–D). At the implantation site, PH26-
Fig. 1. Scheme of procedure from cortical biopsy to autotransplantation.
Schematic representation of the different steps from cortical biopsy to
autotransplantation. Pieces of cerebral cortex were obtained from M.
fascicularis (1). Biopsies were handled as described in supplement to
obtain cortical cell aggregates (2). Cell aggregates were pooled and labeled
with fluorescent viable dyes PKH26 or PKH67 (Sigma) (3). Labeled cells
were stereotaxically re-implanted with a 100-Al Hamilton glass syringe (4).
Fig. 2. Brain histology 1 month after adult brain cell re-implantation.
(A) PKH67 (green)-labeled monkey autotransplanted brain cells in non-
lesioned area. (B) PKH26 (red)-labeled monkey autotransplanted brain
cells near the ibotenic acid-induced lesion. (A–C) Nuclei are counter-
stained with Dapi (blue). (C) Hematoxylin-stained brain section in the
ibotenic acid-induced lesion area, the parallelogram delineates the re-
implanted cell invaded area. (D) Reconstruction of magnifications
corresponding to the parallelogram in panel C after nestin immunolab-
eling. (E) Magnification of an area corresponding to the square in panel
D, near the ibotenic acid-induced lesion. Note that nestin-positive cells
are observed along the ibotenic acid-induced lesion. (A–B: scale bar =












labeled cells still express low level of nestin (Figs. 4A–C).
In the lesioned cortical area, many PKH26-labeled cells
expressed the neuronal marker MAP2 and presented a
neuronal morphology (Figs. 4D–F). No major gliosis was
observed.
Taken together with our previous studies (Brunet et al.,
2002), these results confirm that adult brain cells can be
obtained, cryopreserved, and kept in culture before being
reimplanted in the donor, and survive in vivo. At 3
months, reimplanted cells limit their localization around
the excitotoxic lesion. Moreover these cells exhibit
neuronal characteristics such as MAP2. Nevertheless, the
crucial points that remain to be elucidated are their roles
in brain repair when applied in different models of
neurological disorders. These attractive perspectives and
their potential clinical impact lead us to further develop
the field of autotransplantation in the central nervous
system.
Materials and methods
Preparation of cultured primate brain cells from adult tissue
Pieces of cerebral cortex were obtained from monkey
(M. fascicularis) in accordance with ethical committee
guidelines and authorization of local veterinary authorities.
Biopsy was dissected with a razor blade to obtain
enriched fractions of grey matter. Primary cultures were
generated by mincing and mechanically triturating the
tissue with fire-polished glass pipettes of decreasing
diameters. The resulting cell suspensions were counted
by diluting cell suspension 1:10 in trypan blue stain
(T9520 Sigma). Cells were resuspended at 50,000 cells/ml
in RPMI 1640 medium (Gibco) supplemented with
NaHCO3 44 mM, 20% fetal bovine serum (FBS), and
an antibiotic/antimycotic cocktail (A7292 Sigma) directly
into 25 ml-glass Erlenmeyer at 37-C in a water-saturated
atmosphere containing 6.5% CO2/93.5% air under hori-
zontal agitation at 70 rotations/min. A cell suspension was
plated on glass coverslips into a 24-well plate in same
incubator condition. Fifteen days later, the concentration
of serum was reduced to 10%. After 30–45 days when
cells became confluent on coverslip, cells were cultured in
medium without serum and were maintained in these
conditions.
Re-implantation of cultured primate brain cells into donor
brain
Cell aggregates from one flask were pooled by
centrifugation at 800 rpm, supernatant was recuperated
for resuspension. Aggregates were resuspended in 500 Al
diluent C with 5 AM fluorescent viable dyes PKH26 or
PKH67 (Sigma) for three min. 500 Al FCS was added for
1 min and aggregates washed three time with RPMI
Fig. 4. Immunolabeling of brain section in the ibotenic acid-lesioned
motor cortex, 3 months after adult brain cell re-implantation. (A–C)
Merged image (A) of PKH26 (red) reimplanted cells (B) that express
nestin (green) (C) in the reimplantation site area. (D–F) Merged image
(D) of PKH26 (red)-labeled cells (E) that express MAP2 (green) (F) after
migration toward the lesioned area. White arrows show three PKH26-
positive cells that express MAP2. Nuclei are counterstained with Dapi
(blue) (A–F: scale bar = 15 Am).
Fig. 3. Brain histology 3 months after adult brain cell re-implantation. All
these sections were performed in the ibotenic acid-lesioned motor cortex.
(A) Migration of PKH26 (red)-labeled monkey autotransplanted brain
cells toward the ibotenic acid-induced lesion. The green ellipse
corresponds to the reimplantation site and the blue ellipse represents the
ibotenic acid track. (B–D) Magnification of the small squares in panels A,
B, and C, respectively, in the middle and at the bottom of ibotenic acid-
induced lesion, panel D, in a deeper area without PKH26 reimplanted
cells. Nuclei are counterstained with Dapi (blue). (A: scale bar = 1 mm;











modified medium. After the last wash, aggregates were
resuspended with the recuperated medium previously
centrifuged at 4000 rpm to eliminate cellular wastes.
Tubes containing fluorescent dye-stained aggregates were
completely filled to be transported. For re-implantation
aggregates were settled and resuspended in 100 Al.
Injection was stereotaxically done with a 100-Al Hamilton
glass syringe, cell aggregate suspension was injected by 2
Al/min until 50 Al containing 150,000 cells/site. Into the
left motor-lesioned cortex, three sites were injected with
PKH26-labeled aggregates. Moreover, three sites were
injected with PKH67-labeled aggregates into the normal
parietal cortex.
Immunocytochemistry and immunohistochemistry
After sacrifice, monkeys were perfused with parafor-
maldehyde, brains were then removed, and 8 series of 50-
Am-thick sections were prepared with a cryotome. For cell
cultures, glass coverslips were fixed with 4% paraformal-
dehyde in PBS or with acetone. Cell aggregates in
suspension were polled by centrifugation, supernatant
eliminated, cells were resuspended in 100 Al of medium
and drops with resuspended aggregates were placed on a
glass slice, dried in a 37-C dry air incubator for 1 h and
then fixed with 4% paraformaldehyde in PBS. Brain
cryosection, coverslips, or glass slices were incubated in
PBS with 0.1% casein and then incubated in PBS 0.3%
bovine albumin with antibodies against the following
antigens: glial fibrillary acidic protein (GFAP) (mono-
clonal G3893 Sigma and polyclonal Z0334 Dako,
Glostrup, Denmark), nestin (AB 22 polyclonal Chemicon),
MAP2 (Sigma). They were then washed and incubated
with fluorescent- or horseradish peroxidase-conjugated
secondary antibodies. After the last washes, they were
revealed for peroxidase activity with diaminobenzidine or
mounted in Vectashield\ with Dapi to counterstain nuclei
before fluorescent microscope or confocal microscope
analysis.
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